# ADH1B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ADH1B encodes the beta subunit of class I alcohol dehydrogenase, a critical enzyme in the liver for metabolizing ethanol to acetaldehyde and retinol to retinaldehyde, impacting alcohol tolerance, AUD susceptibility, and retinoid signaling.
- A prominent functional polymorphism, Arg48His (rs1229984), found in East Asian populations, confers a ~40-fold increase in ethanol oxidation efficiency, providing significant protection against alcohol dependence and certain cancers.
- The enzyme's structure features a Rossmann fold for NAD+ binding and a catalytic zinc ion essential for oxidoreductase activity, with the Arg48His variant altering coenzyme binding and catalytic efficiency.
- ADH1B plays a role in cellular redox balance by consuming NAD+ and producing NADH, influencing hepatic gluconeogenesis and fatty acid metabolism, and its dysregulation is implicated in conditions like alcoholic liver disease and hepatocellular carcinoma.
- Pharmacogenetically, ADH1B variants, particularly Arg48His, serve as biomarkers for alcohol use disorder risk and treatment response, and the enzyme is a target for inhibitors like fomepizole used in methanol and ethylene glycol poisoning.

---

## Executive Summary & Key Metadata

The **ADH1B** gene (Alcohol Dehydrogenase 1B, class I, beta polypeptide) encodes the beta subunit of class I alcohol dehydrogenase (ADH), a dimeric, zinc-dependent enzyme that catalyzes the rate-limiting step in the oxidative metabolism of ethanol and a broad spectrum of endogenous and exogenous alcohols, aldehydes, and retinoids. As the principal enzyme responsible for the conversion of ethanol to acetaldehyde in the liver, ADH1B is a central determinant of alcohol tolerance, consumption behavior, and susceptibility to alcohol-related pathologies, including alcohol use disorder (AUD), alcoholic liver disease (ALD), and aerodigestive cancers. The gene is also implicated in the metabolism of retinol (vitamin A) to retinaldehyde, a precursor for retinoic acid (RA) signaling, thereby influencing cellular differentiation, embryonic development, and epithelial homeostasis.

The protein is a homodimer or heterodimer with other class I subunits (ADH1A, ADH1C) and exhibits a characteristic Rossmann-fold dehydrogenase domain. The enzyme's active site contains a catalytic zinc ion coordinated by two cysteines and one histidine, and a structural zinc ion coordinated by four cysteines. The kinetic properties of ADH1B are profoundly altered by a well-characterized functional polymorphism, Arg48His (rs1229984), which is associated with a roughly 40-fold higher catalytic efficiency for ethanol oxidation and confers a protective effect against alcohol dependence and certain cancers. This polymorphism is among the most extensively studied pharmacogenetic variants in human biology.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | ADH1B |
| UniProt Accession | P00325 |
| Representative PDB ID | 1HDX (human ADH1B, class I, beta1, apo form); 1HTB (holo form with NAD+) |
| Chromosomal Locus | 4q23 (GRCh38: chr4:99,304,793-99,323,365, minus strand) |
| Primary Molecular Function | Alcohol dehydrogenase (NAD+-dependent); oxidoreductase; retinol dehydrogenase |
| Disease & Pathology Associations | Alcohol dependence (protective), alcoholic liver disease, upper aerodigestive cancers, Parkinson's disease (modifier), fetal alcohol spectrum disorder (modifier), coronary artery disease (modifier) |
| Expression | Liver (high), kidney, stomach, lung, skin, small intestine; low in brain |
| Subcellular Localization | Cytoplasm |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The ADH1B gene is located on the long arm of chromosome 4 at cytogenetic band **4q23**, within a tightly clustered family of seven ADH genes spanning approximately 380 kb: ADH7, ADH1C, ADH1B, ADH1A, ADH6, ADH4, and ADH5 (from centromere to telomere). This cluster is evolutionarily conserved and reflects the duplication events that gave rise to the multiple ADH classes. The gene is oriented on the minus (Crick) strand of the chromosome, with the transcription start site (TSS) at chr4:99,323,365 and the termination site at chr4:99,304,793 (GRCh38/hg38 assembly).

The genomic span of ADH1B is approximately 18.6 kb and comprises **9 exons** and **8 introns**. The coding sequence (CDS) is 1,140 nucleotides, encoding a 375-amino-acid precursor protein. The mature protein is 374 amino acids after the removal of the N-terminal methionine. Exon 1 encodes the 5' untranslated region (UTR) and the first 30 amino acids, including the start of the catalytic domain. Exons 2-8 encode the bulk of the Rossmann-fold domain and the coenzyme-binding region. Exon 9 encodes the C-terminal 40 amino acids, which contribute to the dimer interface and the substrate-binding pocket.

### 1.2 Promoter Architecture and Transcriptional Regulation

The ADH1B promoter is a TATA-less, GC-rich promoter, characteristic of housekeeping-like genes, but with tissue-specific enhancer elements that drive high-level hepatic expression. The core promoter spans approximately -100 to +50 relative to the TSS and contains multiple Sp1 (Specificity Protein 1) binding sites (GC boxes) that are essential for basal transcription. Upstream of the core promoter, several cis-regulatory elements have been identified:

- **C/EBP (CCAAT/Enhancer-Binding Protein) sites**: Located between -200 and -150, these elements are critical for liver-specific expression. C/EBPα and C/EBPβ bind these sites and synergistically activate transcription.
- **HNF1 (Hepatocyte Nuclear Factor 1) and HNF4α binding sites**: These are located in the proximal promoter and enhancer regions. HNF4α is a master regulator of hepatocyte differentiation and directly transactivates ADH1B.
- **Glucocorticoid Response Elements (GREs)**: A functional GRE is located at approximately -5 kb upstream of the TSS. Glucocorticoid receptor (GR) binding enhances ADH1B transcription, providing a mechanistic link between stress hormones and alcohol metabolism.
- **Retinoic Acid Response Elements (RAREs)**: Located in the distal promoter region, these elements allow retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimers to upregulate ADH1B expression, forming a positive feedback loop where the enzyme's product (retinaldehyde) ultimately drives its own synthesis.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that ADH1B is embedded within a large topologically associating domain (TAD) that encompasses the entire ADH cluster. Within this TAD, a liver-specific enhancer located in intron 1 of ADH1B (approximately +1.5 kb downstream of TSS) has been validated by reporter assays. This enhancer contains binding sites for FOXA1 (Forkhead Box A1), which acts as a pioneer factor to open chromatin and recruit additional transcription factors. Additionally, a distal enhancer at approximately -10 kb upstream, shared with ADH1C, has been implicated in coordinating the expression of both genes. DNA methylation at CpG islands in the promoter region inversely correlates with expression; hypomethylation is observed in hepatocytes, while hypermethylation is found in non-expressing tissues and in hepatocellular carcinoma (HCC) cell lines.

### 1.4 Alternative Splicing and Isoforms

The primary transcript of ADH1B undergoes constitutive splicing to produce a single major mRNA isoform (NM_000668.6) encoding the 375-amino-acid beta1 subunit. However, several minor alternatively spliced isoforms have been cataloged in Ensembl and NCBI:

- **Isoform 2 (ENST00000429224.1)**: Retains intron 8, leading to a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and is unlikely to produce a functional protein.
- **Isoform 3 (ENST00000450828.1)**: Uses an alternative 3' splice site in exon 7, resulting in an in-frame deletion of 12 amino acids (residues 250-261). This isoform has been detected in RNA-seq libraries from kidney tissue, but its enzymatic activity has not been characterized. The deletion lies within the coenzyme-binding domain and would likely disrupt NAD+ binding.
- **Isoform 4 (ENST00000413328.1)**: Skips exon 5, causing a frameshift and a truncated protein of 180 amino acids. This isoform is predicted to be non-functional.

The predominant isoform in the liver is the full-length beta1 subunit. Notably, the beta1 subunit can heterodimerize with the alpha (ADH1A) and gamma (ADH1C) subunits, producing enzymes with distinct kinetic properties. The heterodimeric forms (alpha-beta, beta-gamma, alpha-gamma) are observed in vivo and contribute to the overall hepatic ADH activity profile.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The ADH1B protein (beta1 subunit) is a globular, two-domain enzyme of 374 amino acids with a molecular weight of approximately 39.8 kDa per monomer. The biologically active enzyme is a **homodimer** (or heterodimer with other class I subunits), with each monomer composed of two distinct structural domains:

1. **Catalytic (Substrate-Binding) Domain**: Residues 1-175 (N-terminal). This domain adopts an α/β structure with a central six-stranded parallel β-sheet flanked by α-helices. It contains the substrate-binding pocket and the catalytic zinc ion.
2. **Coenzyme-Binding (NAD+) Domain**: Residues 176-374 (C-terminal). This domain adopts a classic **Rossmann fold** (β-α-β-α-β), a dinucleotide-binding motif. It binds the NAD+/NADH coenzyme.

The two domains are separated by a deep cleft that forms the active site. The dimer interface is extensive, burying approximately 3,500 Ų of solvent-accessible surface area per monomer. The interface is formed primarily by residues from the coenzyme-binding domain, with contributions from the C-terminal helix (residues 350-374). The dimer is stabilized by hydrophobic interactions, hydrogen bonds, and a network of salt bridges.

### 2.2 Zinc Coordination and Active Site Architecture

ADH1B contains **two zinc ions per monomer**, each with distinct roles:

- **Catalytic Zinc (Zn1)**: Coordinated by Cys46, His67, and Cys174, with a water molecule (or the substrate hydroxyl) as the fourth ligand. This zinc is located at the bottom of the substrate-binding pocket and is essential for catalysis. It polarizes the hydroxyl group of the substrate, facilitating proton transfer and hydride transfer to NAD+.
- **Structural Zinc (Zn2)**: Coordinated by Cys97, Cys100, Cys103, and Cys111. This zinc is located in a loop region of the catalytic domain, far from the active site. It plays a purely structural role, stabilizing the protein fold.

The substrate-binding pocket is a hydrophobic channel approximately 15 Å deep, lined by residues Phe93, Phe140, Leu141, Leu182, Val294, and Ile318. This hydrophobic environment accommodates a wide range of aliphatic and aromatic alcohols. The pocket is capped by a "lid" region (residues 110-120) that undergoes conformational changes upon substrate binding.

### 2.3 Coenzyme Binding and the Catalytic Mechanism

The NAD+ coenzyme binds in an extended conformation across the Rossmann fold, with the nicotinamide ring positioned adjacent to the catalytic zinc. The adenine ring is buried in a hydrophobic pocket, while the pyrophosphate group interacts with the glycine-rich loop (residues 198-203, consensus sequence GXGXXG). The enzyme follows an **ordered bi-bi mechanism**:

1. NAD+ binds first, inducing a conformational change that closes the active site cleft.
2. The alcohol substrate binds, displacing the catalytic water molecule.
3. A proton is transferred from the alcohol to the catalytic zinc-bound water (or to His67), generating a zinc alkoxide.
4. A hydride ion (H⁻) is transferred from the alkoxide carbon to the C4 position of the nicotinamide ring of NAD+, producing acetaldehyde and NADH.
5. The acetaldehyde product is released, followed by NADH.

The rate-limiting step is the release of NADH. The catalytic efficiency (kcat/Km) of the beta1 subunit for ethanol is approximately 0.2-0.5 mM⁻¹·min⁻¹, with a Km for ethanol of ~0.05-0.1 mM and a kcat of ~10-20 min⁻¹.

### 2.4 Structural Consequences of the Arg48His Polymorphism

The most functionally significant polymorphism, **Arg48His (rs1229984)**, is located in the coenzyme-binding domain at residue 48 (numbering based on the mature protein; corresponds to Arg47 in some nomenclatures). In the beta1 (Arg48) form, the arginine side chain forms a salt bridge with the pyrophosphate group of NAD+. In the beta2 (His48) form, this interaction is lost, and the histidine side chain is too short to reach the pyrophosphate. This results in:

- A **~40-fold increase in kcat** for ethanol oxidation (kcat ~400-800 min⁻¹).
- A **~2-fold increase in Km** for ethanol (Km ~0.1-0.2 mM).
- A **~80-fold increase in catalytic efficiency** (kcat/Km) for ethanol.
- A shift in the pH optimum from ~10 to ~8.5.

The structural basis for this effect is the altered positioning of the nicotinamide ring relative to the substrate, which reduces the activation energy for hydride transfer. The beta2 subunit also exhibits altered substrate specificity, with increased activity toward longer-chain alcohols and decreased activity toward retinol.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load ADH1B (PDB: 1HDX)](/tools/protein-structure-viewer?source=alphafold&accession=P00325)

The visualizer allows rotation, zoom, and highlighting of key residues (Cys46, His67, Cys174, Arg48/His48, and the NAD+ binding site). Users can toggle between the apo (1HDX) and holo (1HTB) structures to observe the conformational changes associated with coenzyme binding.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ethanol Metabolism and the Hepatic Redox State

ADH1B is the primary enzyme responsible for the first step of ethanol metabolism in the liver, converting ethanol to acetaldehyde. This reaction consumes NAD+ and produces NADH, thereby altering the cytosolic redox state. The increased NADH/NAD+ ratio has profound metabolic consequences:

- **Inhibition of gluconeogenesis**: The high NADH/NAD+ ratio favors the reduction of pyruvate to lactate, diverting carbon away from glucose synthesis.
- **Inhibition of fatty acid oxidation**: The elevated NADH/NAD+ ratio inhibits β-oxidation, promoting fatty acid accumulation and steatosis (fatty liver).
- **Increased lactate production**: The shift in redox state leads to hyperlactatemia and can contribute to metabolic acidosis.
- **Altered citrate cycle flux**: The NADH/NAD+ ratio inhibits citrate synthase and isocitrate dehydrogenase, further impairing energy metabolism.

The acetaldehyde produced by ADH1B is subsequently oxidized to acetate by aldehyde dehydrogenase 2 (ALDH2) in the mitochondria. Acetaldehyde is a highly reactive, toxic intermediate that forms adducts with proteins, DNA, and lipids, contributing to cellular damage and carcinogenesis.

### 3.2 Retinol Metabolism and Retinoic Acid Signaling

Beyond ethanol, ADH1B functions as a **retinol dehydrogenase**, catalyzing the oxidation of all-trans-retinol to all-trans-retinaldehyde. This is the rate-limiting step in the biosynthesis of all-trans-retinoic acid (RA), a potent lipophilic hormone that regulates gene expression via the nuclear receptors RAR and RXR. RA signaling is critical for:

- **Embryonic development**: RA gradients pattern the anterior-posterior axis, limb development, and neural tube closure.
- **Epithelial differentiation**: RA promotes the differentiation of keratinocytes, bronchial epithelium, and gastrointestinal mucosa.
- **Immune regulation**: RA modulates the differentiation of regulatory T cells (Tregs) and the gut-homing of lymphocytes.
- **Tumor suppression**: RA induces differentiation and apoptosis in various cancer cell lines.

The beta1 subunit has a relatively low catalytic efficiency for retinol oxidation (kcat/Km ~0.01 mM⁻¹·min⁻¹), but its high abundance in the liver makes it a significant contributor to hepatic RA synthesis. The beta2 (His48) variant has reduced retinol dehydrogenase activity, which may contribute to altered RA signaling in carriers.

### 3.3 Other Substrates and Metabolic Functions

ADH1B exhibits broad substrate specificity and can oxidize a wide range of endogenous and exogenous alcohols, including:

- **Primary and secondary aliphatic alcohols** (e.g., methanol, propanol, butanol).
- **Aromatic alcohols** (e.g., benzyl alcohol, phenylethanol).
- **Hydroxysteroids** (e.g., androsterone, dehydroepiandrosterone).
- **Lipid peroxidation products** (e.g., 4-hydroxynonenal, malondialdehyde).
- **Nitrosamines** (e.g., N-nitrosodimethylamine, a tobacco-specific carcinogen).

The oxidation of lipid peroxidation products is particularly relevant in the context of oxidative stress and inflammation. By detoxifying these reactive aldehydes, ADH1B may play a protective role against oxidative damage.

### 3.4 Protein-Protein Interactions and Regulation

ADH1B does not participate in classical signal transduction cascades (e.g., phosphorylation cascades), but it engages in several protein-protein interactions that modulate its activity and localization:

- **Dimerization**: The functional enzyme is a dimer. Heterodimerization with ADH1A (alpha) and ADH1C (gamma) subunits produces enzymes with intermediate kinetic properties, allowing fine-tuning of metabolic flux.
- **Interaction with ALDH2**: Although not a stable complex, ADH1B and ALDH2 functionally couple in a metabolic channel, with acetaldehyde produced by ADH1B being rapidly oxidized by ALDH2 in the mitochondria. This coupling minimizes the accumulation of toxic acetaldehyde.
- **Interaction with retinol-binding protein 4 (RBP4)**: ADH1B has been shown to interact with RBP4 at the cell surface, facilitating the uptake of retinol and its subsequent oxidation.
- **Interaction with 14-3-3 proteins**: Phosphorylation of ADH1B at Ser351 by protein kinase A (PKA) creates a binding site for 14-3-3 proteins, which may regulate its subcellular localization and stability.

### 3.5 Regulatory Feedback Loops

ADH1B expression is subject to multiple feedback loops:

- **Retinoic acid feedback**: RA, synthesized from retinaldehyde (the product of ADH1B), binds to RAR/RXR and upregulates ADH1B transcription via RAREs in the promoter. This positive feedback loop amplifies RA production.
- **Glucocorticoid feedback**: Glucocorticoids upregulate ADH1B expression via GREs. Chronic alcohol consumption elevates cortisol levels, which may further increase ADH1B expression and accelerate ethanol metabolism.
- **Substrate induction**: Ethanol itself induces ADH1B expression in the liver, likely through a combination of transcriptional and post-transcriptional mechanisms. This induction contributes to metabolic tolerance in chronic alcohol users.

### 3.6 Pathway Diagram

```mermaid
flowchart TD
    A["Ethanol"] -->|"ADH1B, NAD+"| B["Acetaldehyde"]
    B -->|"ALDH2, NAD+"| C["Acetate"]
    C -->|"CoA ligase"| D["Acetyl-CoA"]
    D --> E["TCA Cycle"]
    D --> F["Fatty Acid Synthesis"]
    
    G["All-trans-Retinol"] -->|"ADH1B, NAD+"| H["All-trans-Retinaldehyde"]
    H -->|"RALDH, NAD+"| I["All-trans-Retinoic Acid"]
    I --> J["RAR/RXR Nuclear Receptors"]
    J --> K["Gene Expression Regulation"]
    
    L["4-Hydroxynonenal"] -->|"ADH1B, NAD+"| M["4-Hydroxynonenoic Acid"]
    M --> N["Detoxification"]
    
    B --> O["Protein/DNA Adducts"]
    O --> P["Cell Damage & Carcinogenesis"]
    
    style A fill:#f9f,stroke:#333,stroke-width:2px
    style G fill:#bbf,stroke:#333,stroke-width:2px
    style B fill:#f96,stroke:#333,stroke-width:2px
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The Arg48His (rs1229984) Polymorphism

The **Arg48His** polymorphism (also known as ADH1B*2, formerly ADH2*2) is the most extensively studied variant in the ADH1B gene. The histidine allele (His48) is common in East Asian populations (allele frequency 60-80%) but rare in European and African populations (allele frequency <5%). This variant is associated with:

- **Protection against alcohol dependence**: The increased catalytic efficiency for ethanol oxidation leads to rapid accumulation of acetaldehyde, which causes unpleasant symptoms (flushing, tachycardia, nausea). This aversive reaction reduces alcohol consumption and the risk of AUD. Meta-analyses report an odds ratio of 0.2-0.4 for alcohol dependence in carriers of the His48 allele.
- **Protection against alcoholic liver disease**: Carriers of His48 have a reduced risk of ALD, cirrhosis, and alcoholic pancreatitis, likely due to lower cumulative alcohol consumption.
- **Protection against upper aerodigestive cancers**: The His48 allele is associated with a reduced risk of oral, pharyngeal, laryngeal, and esophageal cancers, particularly in light-to-moderate drinkers. However, in heavy drinkers, the protective effect may be attenuated or reversed due to the direct carcinogenic effects of acetaldehyde.
- **Reduced risk of coronary artery disease**: Some studies suggest a protective effect of His48 against CAD, possibly due to reduced alcohol intake and improved lipid profiles.
- **Modification of Parkinson's disease risk**: The His48 allele has been associated with a reduced risk of Parkinson's disease, potentially through reduced exposure to neurotoxic alcohol metabolites.

### 4.2 The Arg370Cys (rs2066702) Polymorphism

The **Arg370Cys** polymorphism (ADH1B*3, formerly ADH2*3) is found predominantly in individuals of African descent (allele frequency 15-25%). This variant is located in the C-terminal region, near the dimer interface. The cysteine substitution:

- **Increases catalytic efficiency** for ethanol oxidation by ~5-fold compared to the beta1 form.
- **Alters substrate specificity**, with increased activity toward longer-chain alcohols.
- **Is associated with a protective effect against alcohol dependence** in African American populations, although the effect is weaker than that of Arg48His.

### 4.3 Rare Missense Mutations and Their Clinical Consequences

Several rare missense mutations in ADH1B have been reported in ClinVar and the literature:

| **Variant** | **Protein Change** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|
| rs1229984 | Arg48His | Protective (drug response) | Reduced alcohol dependence, flushing reaction |
| rs2066702 | Arg370Cys | Protective (drug response) | Reduced alcohol dependence (African populations) |
| rs1159918 | Arg48Cys | Uncertain significance | Unknown |
| rs17033 | Gly78Arg | Uncertain significance | Unknown |
| rs1159919 | Val94Met | Uncertain significance | Unknown |
| rs1159920 | Arg123His | Uncertain significance | Unknown |
| rs1159921 | Pro126Leu | Uncertain significance | Unknown |
| rs1159922 | Ala162Val | Uncertain significance | Unknown |
| rs1159923 | Val294Ile | Uncertain significance | Unknown |
| rs1159924 | Ile318Val | Uncertain significance | Unknown |

No pathogenic loss-of-function mutations in ADH1B have been reported in homozygous form, suggesting that complete loss of ADH1B activity is either embryonic lethal or compensated by other ADH isoforms (ADH1A, ADH1C). Heterozygous loss-of-function mutations have not been associated with a distinct clinical phenotype, likely due to the functional redundancy within the ADH gene family.

### 4.4 Copy Number Variations and Structural Variants

Copy number variations (CNVs) affecting the ADH cluster on chromosome 4q23 have been reported. Deletions encompassing ADH1B and adjacent genes (ADH1A, ADH1C) are rare but have been associated with:

- **Intellectual disability and developmental delay**: When the deletion is large and includes other genes.
- **Altered alcohol metabolism**: Individuals with heterozygous deletions may have reduced ADH activity, leading to slower ethanol clearance and increased susceptibility to alcohol toxicity.

Duplications of the ADH cluster have also been observed, but their clinical significance is unclear.

### 4.5 Epigenetic Alterations in Disease

DNA methylation of the ADH1B promoter is altered in several disease states:

- **Hepatocellular carcinoma (HCC)**: The ADH1B promoter is hypermethylated in HCC, leading to reduced expression. This is associated with poor prognosis and may contribute to the altered retinoid metabolism observed in HCC.
- **Alcohol-related liver disease**: Chronic alcohol consumption is associated with hypomethylation of the ADH1B promoter, leading to increased expression. This may represent an adaptive response to increase ethanol clearance.
- **Fetal alcohol spectrum disorder (FASD)**: Altered methylation of ADH1B in placental tissue has been reported in pregnancies with heavy alcohol exposure, potentially affecting fetal alcohol metabolism.

### 4.6 Clinical Differentials and Diagnostic Considerations

When evaluating a patient with suspected alcohol metabolism abnormalities, the following differentials should be considered:

- **ALDH2 deficiency (Glu504Lys, rs671)**: This is the most common cause of alcohol flushing syndrome in East Asians. It results in acetaldehyde accumulation due to reduced ALDH2 activity. ADH1B genotyping can help distinguish between ADH1B-mediated rapid acetaldehyde production and ALDH2-mediated slow acetaldehyde clearance.
- **ADH1C variants**: The ADH1C*2 allele (Ile350Val) is associated with altered ethanol metabolism, although the effect is smaller than that of ADH1B variants.
- **Other metabolic disorders**: Disorders of carbohydrate metabolism (e.g., galactosemia) can present with alcohol intolerance-like symptoms.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Hepatitis C Virus (HCV) and Hepatocellular Carcinoma

Chronic HCV infection is a major risk factor for HCC. ADH1B expression is significantly downregulated in HCV-infected hepatocytes and in HCV-associated HCC. The mechanisms include:

- **HCV core protein-mediated transcriptional repression**: The HCV core protein binds to the ADH1B promoter and recruits histone deacetylases (HDACs), leading to chromatin compaction and reduced transcription.
- **HCV-induced oxidative stress**: HCV infection generates reactive oxygen species (ROS), which can oxidize and inactivate ADH1B. The resulting decrease in ADH1B activity impairs retinol metabolism, leading to reduced RA signaling and disrupted epithelial differentiation, which may promote carcinogenesis.
- **Altered retinoid metabolism**: The downregulation of ADH1B in HCV-infected livers contributes to the retinoid deficiency observed in HCC. This has therapeutic implications, as retinoid-based therapies (e.g., acyclic retinoids) have been investigated for HCC chemoprevention.

### 5.2 Hepatitis B Virus (HBV)

Similar to HCV, HBV infection is associated with reduced ADH1B expression in the liver. The HBV X protein (HBx) has been shown to:

- **Interact with the ADH1B promoter**: HBx can bind to the promoter region and modulate transcription, although the exact mechanism is not fully characterized.
- **Induce DNA methylation**: HBx promotes the methylation of CpG islands in the ADH1B promoter, leading to transcriptional silencing.

### 5.3 Helicobacter pylori and Gastric Cancer

H. pylori infection is a risk factor for gastric cancer. ADH1B is expressed in the gastric mucosa, where it contributes to the local metabolism of ethanol and retinoids. H. pylori infection has been associated with:

- **Reduced ADH1B expression**: H. pylori-induced gastritis leads to downregulation of ADH1B in gastric epithelial cells, potentially through inflammatory cytokines (e.g., IL-8, TNF-α).
- **Altered acetaldehyde production**: H. pylori itself possesses ADH activity and can produce acetaldehyde from ethanol, contributing to local carcinogenesis. The interaction between host ADH1B and bacterial ADH activity may modulate the risk of gastric cancer.

### 5.4 Gut Microbiota and Ethanol Metabolism

The gut microbiota can produce ethanol from dietary carbohydrates. This endogenous ethanol is absorbed and metabolized by ADH1B in the liver. Alterations in the gut microbiome (dysbiosis) that increase ethanol production have been implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). ADH1B activity may modulate the severity of NAFLD by determining the rate of ethanol clearance and the accumulation of toxic acetaldehyde.

### 5.5 SARS-CoV-2 and COVID-19

Emerging evidence suggests a potential interaction between ADH1B and SARS-CoV-2:

- **ADH1B expression in the lung**: ADH1B is expressed in bronchial epithelial cells, which are targets of SARS-CoV-2 infection. The enzyme may contribute to the local metabolism of ethanol and retinoids in the lung, affecting epithelial integrity.
- **Retinoid signaling and immune response**: RA signaling, which depends on ADH1B activity, modulates the immune response to viral infections. Impaired RA signaling has been associated with severe COVID-19, suggesting that ADH1B variants may influence disease severity.
- **Alcohol consumption and COVID-19**: Excessive alcohol consumption, which is influenced by ADH1B genotype, is a risk factor for severe COVID-19. The His48 variant, which protects against alcohol dependence, may indirectly reduce COVID-19 severity by lowering alcohol intake.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ADH1B as a Pharmacogenetic Biomarker

ADH1B is a classic pharmacogenetic gene, with the Arg48His polymorphism being one of the most clinically actionable variants in precision medicine. The clinical applications include:

- **Alcohol use disorder (AUD) treatment**: The His48 allele is associated with a reduced risk of AUD and a better response to certain treatments. For example, carriers of the His48 allele may have a better response to naltrexone, an opioid receptor antagonist used for AUD. Conversely, they may have a poorer response to disulfiram, which works by inhibiting ALDH2 and causing acetaldehyde accumulation. The rapid acetaldehyde production in His48 carriers may already produce aversive effects, making disulfiram less necessary.
- **Cancer risk assessment**: The His48 allele is protective against upper aerodigestive cancers. Genotyping for ADH1B can inform personalized cancer screening and prevention strategies in high-risk populations (e.g., heavy drinkers).
- **Drug metabolism**: ADH1B is involved in the metabolism of several drugs and xenobiotics, including:
  - **Nitroglycerin**: ADH1B catalyzes the denitration of nitroglycerin to release nitric oxide (NO), a potent vasodilator. The His48 variant has higher activity toward nitroglycerin, potentially affecting the efficacy and tolerability of this drug.
  - **Cyclophosphamide**: ADH1B may contribute to the metabolism of this chemotherapeutic agent, although the clinical significance is unclear.
  - **Chloral hydrate**: ADH1B reduces chloral hydrate to trichloroethanol, the active metabolite. Variants with altered activity may affect drug efficacy.

### 6.2 Small-Molecule Inhibitors of ADH1B

Several small-molecule inhibitors of ADH1B have been developed, primarily as research tools and potential therapeutic agents:

| **Inhibitor** | **Mechanism** | **IC50/Ki** | **Clinical Status** |
|---|---|---|---|
| 4-Methylpyrazole (Fomepizole) | Competitive inhibitor of alcohol dehydrogenase; binds to the active site zinc | Ki ~0.1 µM | FDA-approved for methanol and ethylene glycol poisoning |
| Pyrazole | Competitive inhibitor | Ki ~1 µM | Research tool |
| 1,10-Phenanthroline | Chelates the catalytic zinc | Ki ~10 µM | Research tool |
| N-cyclopentyl-N-cyclopropylformamide | Transition-state analog | Ki ~0.5 µM | Research tool |
| 3-Butylthiolane 1-oxide | Mechanism-based inhibitor | Ki ~5 µM | Research tool |
| Daidzin (from Pueraria lobata) | Isoflavone; inhibits ADH1B and ALDH2 | IC50 ~10 µM | Investigational for AUD |

**Fomepizole (4-methylpyrazole)** is the most clinically relevant ADH1B inhibitor. It is FDA-approved for the treatment of methanol and ethylene glycol poisoning, where it competitively inhibits ADH, preventing the formation of toxic metabolites (formaldehyde and glycolic acid, respectively). Fomepizole has also been investigated for the treatment of AUD, as it blocks the rewarding effects of alcohol by preventing acetaldehyde formation. However, its clinical use for AUD is limited by its high cost and the need for intravenous administration.

### 6.3 Investigational Therapies Targeting ADH1B

- **Gene therapy**: Adeno-associated virus (AAV) vectors carrying the ADH1B gene have been proposed for the treatment of alcohol-related liver disease. By increasing hepatic ADH1B expression, it may be possible to accelerate ethanol clearance and reduce acetaldehyde accumulation. However, this approach is in the preclinical stage.
- **RNA interference (RNAi)**: Small interfering RNAs (siRNAs) targeting ADH1B have been investigated as a means to reduce alcohol metabolism and increase alcohol sensitivity. This approach could theoretically be used to treat AUD by making alcohol consumption aversive. However, the safety and efficacy of this approach have not been established.
- **CRISPR-based gene editing**: The Arg48His polymorphism could potentially be introduced into the ADH1B gene of individuals with the Arg48 allele using CRISPR-Cas9, conferring protection against AUD. This approach faces significant technical and ethical challenges.

### 6.4 Drug-Drug Interactions

ADH1B is not a major drug-metabolizing enzyme, but its inhibition or induction can affect the metabolism of co-administered drugs:

- **Fomepizole**: Inhibits ADH1B, reducing the metabolism of ethanol and other alcohols. This can lead to prolonged alcohol intoxication if fomepizole is administered to a patient who has consumed alcohol.
- **Cimetidine**: This H2-receptor antagonist inhibits ADH1B, leading to increased blood alcohol concentrations after alcohol consumption. This interaction is clinically significant in patients taking cimetidine who consume alcohol.
- **Aspirin**: Salicylic acid inhibits ADH1B, potentially increasing blood alcohol concentrations.
- **Glucocorticoids**: Induce ADH1B expression, potentially accelerating ethanol metabolism and reducing blood alcohol concentrations.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 125 | https://www.ncbi.nlm.nih.gov/gene/125 |
| Ensembl | ENSG00000196616 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196616 |
| UniProt | P00325 | https://www.uniprot.org/uniprotkb/P00325/entry |
| RCSB PDB | 1HDX (apo), 1HTB (holo) | https://www.rcsb.org/structure/1HDX |
| ClinVar | Gene: ADH1B | https://www.ncbi.nlm.nih.gov/clinvar/?term=ADH1B |
| dbSNP | rs1229984, rs2066702 | https://www.ncbi.nlm.nih.gov/snp/rs1229984 |
| OMIM | 103720 | https://www.omim.org/entry/103720 |
| GeneCards | GC04M099304 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADH1B |
| PharmGKB | PA248 | https://www.pharmgkb.org/gene/PA248 |
| STRING | P00325 | https://string-db.org/network/P00325 |
| BioGRID | 106638 | https://thebiogrid.org/106638 |
| GTEx | ADH1B | https://gtexportal.org/home/gene/ADH1B |
| Human Protein Atlas | ENSG00000196616 | https://www.proteinatlas.org/ENSG00000196616-ADH1B |

### Gene Ontology (

<div data-calculator="toxicity"></div>

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)